UGP2 has been recognized as a crucial factor in cancer maintenance and has emerged as a potential therapeutic target in pancreatic ductal adenocarcinoma (PDAC) [31]. This evidence concerns the gene UGP2 and pancreatic ductal adenocarcinoma.